AJG-22-1844 674..684

INTRODUCTION: Many patients with Crohn's disease (CD) lose response or become intolerant to antitumor necrosis factor (TNF) therapy and subsequently switch out of class. We compared the effectiveness and safety of ustekinumab to vedolizumab in a large, geographically diverse US population of TNF-experienced patients with CD. METHODS: We conducted a retrospective cohort study using longitudinal claims data from a large US insurer (Anthem, Inc.). We identified patients with CD initiating vedolizumab or ustekinumab with anti-TNF treatment in the prior 6 months. Our primary outcome was treatment persistence for >52 weeks. Secondary outcomes included (i) all-cause hospitalization, (ii) hospitalization for CD with surgery, (iii) hospitalization for CD without surgery, and (iv) hospitalization for infection. Propensity score fine stratification was used to control for demographic and baseline clinical characteristics and prior treatments. RESULTS: Among 885 new users of ustekinumab and 490 new users of vedolizumab, we observed no difference in treatment persistence (adjusted risk ratio 1.09 [95% confidence interval 0.95–1.25]). Ustekinumab was associated with a lower rate of all-cause hospitalization (adjusted hazard ratio 0.73 [0.59–0.91]), nonsurgical CD hospitalization (adjusted hazard ratio 0.58 [0.40–0.83]), and hospitalization for infection (adjusted hazard ratio 0.56 [0.34–0.92]). DISCUSSION: This real-world comparative effectiveness study of anti-TNF-experienced patients with CD initiating vedolizumab or ustekinumab showed similar treatment persistence rates beyond 52 weeks, although secondary outcomes such as all-cause hospitalizations, nonsurgical CD hospitalizations, and hospitalizations for infection favored ustekinumab initiation. We, therefore, advocate for individualized decision making in this medically refractory population, considering patient preference and other factors such as cost and route of administration.

[1]  G. Fiorino,et al.  An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn's Disease Patients' Failure to TNF-Alpha Inhibitors , 2022, The American journal of gastroenterology.

[2]  F. Carbonnel,et al.  Systematic review with meta‐analysis: the effectiveness of either ustekinumab or vedolizumab in patients with Crohn's disease refractory to anti‐tumour necrosis factor , 2021, Alimentary pharmacology & therapeutics.

[3]  Harminder Singh,et al.  AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease. , 2021, Gastroenterology.

[4]  A. de Silvestri,et al.  A propensity score‐matched, real‐world comparison of ustekinumab vs vedolizumab as a second‐line treatment for Crohn’s disease. The Cross Pennine study II , 2021, Alimentary pharmacology & therapeutics.

[5]  B. Flourié,et al.  Comparison of short‐ and long‐term effectiveness between ustekinumab and vedolizumab in patients with Crohn's disease refractory to anti‐tumour necrosis factor therapy , 2021, Alimentary pharmacology & therapeutics.

[6]  Charles E. Leonard,et al.  Validity of ICD‐10‐CM diagnoses to identify hospitalizations for serious infections among patients treated with biologic therapies , 2021, Pharmacoepidemiology and drug safety.

[7]  Philip Smith,et al.  Comparative effectiveness of ustekinumab or vedolizumab after one year in 130 patients with anti‐TNF‐refractory Crohn’s disease , 2020, Alimentary pharmacology & therapeutics.

[8]  E. Oger,et al.  Association Between Early Severe Cardiovascular Events and the Initiation of Treatment With the Anti-Interleukin 12/23p40 Antibody Ustekinumab. , 2020, JAMA dermatology.

[9]  D. D. de Jong,et al.  Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn’s disease patients with prior failure to anti‐TNF treatment , 2020, Alimentary pharmacology & therapeutics.

[10]  A. Amiot,et al.  The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti‐tumour necrosis factor , 2020, Alimentary pharmacology & therapeutics.

[11]  Bruce H Fireman,et al.  Inverse probability weighted Cox model in multi-site studies without sharing individual-level data , 2020, Statistical methods in medical research.

[12]  Jessica M Franklin,et al.  Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners , 2019, BMJ.

[13]  V. Andersen,et al.  Natural disease course of Crohn’s disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study , 2018, Gut.

[14]  Sengwee Toh,et al.  Adaptation and Validation of the Combined Comorbidity Score for ICD-10-CM , 2017, Medical care.

[15]  C. Brensinger,et al.  Increasing Incidence of Multiply Recurrent Clostridium difficile Infection in the United States , 2017, Annals of Internal Medicine.

[16]  S. Vermeire,et al.  Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis , 2017, The New England journal of medicine.

[17]  Krista F. Huybrechts,et al.  A Propensity-score-based Fine Stratification Approach for Confounding Adjustment When Exposure Is Infrequent , 2017, Epidemiology.

[18]  S. Vermeire,et al.  Efficacy of Vedolizumab Induction and Maintenance Therapy in Patients With Ulcerative Colitis, Regardless of Prior Exposure to Tumor Necrosis Factor Antagonists , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[19]  H. Tilg,et al.  3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1 Diagnosis and Medical Management , 2017, Journal of Crohn's & colitis.

[20]  B. Sands,et al.  Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy , 2017, Inflammatory bowel diseases.

[21]  T. Molnár,et al.  Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management. , 2017, Journal of Crohn's & colitis.

[22]  P. Rutgeerts,et al.  Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. , 2016, The New England journal of medicine.

[23]  David B Richardson,et al.  The Active Comparator, New User Study Design in Pharmacoepidemiology: Historical Foundations and Contemporary Application , 2015, Current Epidemiology Reports.

[24]  M. Regueiro,et al.  Ulcerative Colitis Care Pathway. , 2015, Gastroenterology.

[25]  A. Bitton,et al.  Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis: the Toronto consensus. , 2015, Gastroenterology.

[26]  A. Ananthakrishnan,et al.  Impact of Mode of Delivery on Outcomes in Patients with Perianal Crohn's Disease , 2014, Inflammatory bowel diseases.

[27]  T. Dassopoulos,et al.  American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease. , 2013, Gastroenterology.

[28]  G. D'Haens,et al.  Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. , 2012, Gastroenterology.

[29]  L. Tamariz,et al.  A systematic review of validated methods for identifying venous thromboembolism using administrative and claims data , 2012, Pharmacoepidemiology and Drug Safety.

[30]  L. Peyrin-Biroulet,et al.  Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review , 2011, The American Journal of Gastroenterology.

[31]  S. Finlayson,et al.  Trends in Surgery for Crohn's Disease in the Era of Infliximab , 2008, Annals of Surgery.

[32]  P. Rutgeerts,et al.  Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. , 2009, Gastroenterology.

[33]  Peter C. Austin,et al.  Using the Standardized Difference to Compare the Prevalence of a Binary Variable Between Two Groups in Observational Research , 2009, Commun. Stat. Simul. Comput..

[34]  K. Van Steen,et al.  Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a single-centre cohort , 2008, Gut.